Cardiaccs AS has developed a patented solution – CardiaSense (CS) – for monitoring of heart function in patients undergoing open-heart surgeries. The novelty of CS lies in the unique combination of an accelerometer with a conventional temporary pacemaker lead, which surgeons already routinely place on the heart surface during surgeries. CS performs the accurate, real-time, and continuous monitoring of heart function during and after surgeries, with zero footprint on clinical routines and no need for specialized staff to interpret cardiac metrics. Importantly, it enables the very early and actionable detection of heart disorders before patients develop critical symptoms. With CS v1.0 clinical trials initiated, we are now aiming at an upgraded CS v2.0 version, with superior clinical performance and operability. Based on its added-values features, CS has good prospects to become the new gold standard to monitor and manage cardiac surgical patients. The main barriers for Cardiaccs going forward are related to prevailing technical and market-related challenges. Cardiaccs will lead the project, which will focus on product development, maturation, preparation of the market launch and commercialization. This project will enable performing the optimization of CS V2.0 by improving the software and hardware, preparing testing activities and clinical studies to reach the CE certification, demonstrating the product to end-users (cardiologists and cardiothoracic surgeons) and preparing the market launch in Europe. The EIC Accelerator program provides a unique opportunity for Cardiaccs to showcase the potential of our innovation and gain market intelligence. The completion of the project objectives is important for ensuring a successful entrance to the market and commercialization of CS V2.0.
Project leader: Jonas Tyssø
Institution: CARDIACCS AS